Medytox

What Medytox does

Medytox Inc. is a South Korean biopharmaceutical company founded in 2000 by botulinum toxin researchers and listed on the KOSDAQ exchange (ticker: 086900) since 2009. The company develops, manufactures, and commercializes botulinum toxin type A products (Neuronox/Meditoxin, Innotox, Coretox, NEWLUX), hyaluronic acid dermal fillers (Neuramis, Atiere, Potenfill), dermacosmetic products under the Neuraderm brand, and health supplements. Medytox is the first Korean company to develop a botulinum toxin product and is the only company globally to have developed three distinct botulinum toxin formulations, including Innotox — the world's first non-animal derived liquid formulation. The company holds approximately 40% domestic market share in Korea's botulinum toxin market and exports to approximately 60 countries.

The company's core technology is built on proprietary botulinum toxin culture, separation, and refinement capabilities developed by its founding research team, with manufacturing concentrated across three cGMP-compliant facilities in Ochang and Osong, South Korea. Medytox operates an integrated R&D-to-commercialization infrastructure, including a 13-floor biological laboratory in Gwanggyo and dedicated R&D centers in Osong, with reported R&D investment exceeding 15% of total sales. The company is the inventor of NUVIJU (MT921), the world's first cholic acid-based injection lipolysis approved by Korea's MFDS, and is expanding its portfolio into adjacent aesthetic and therapeutic categories.

Medytox's business model is B2B-direct-to-medical-professional: products are sold exclusively to qualified doctors, dermatologists, plastic surgeons, and aesthetic clinics. Domestic sales are handled through wholly-owned subsidiary NUMECO, while international sales flow through a layered network of wholly-owned subsidiaries (Luvantas in the USA, MDT International in Japan, Medytox Thailand), joint ventures (Medytox Taiwan, Medytox Hong Kong, MedyCeles in Thailand), and exclusive distributors (e.g., AMG in Europe). Pricing is not publicly disclosed and is handled through direct purchasing inquiry. The company reports quarterly cash dividends and conducts share repurchases as part of its shareholder return program.

Name

Medytox

Legal name

Medytox Inc.

Website

https://medytox.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Medytox is a South Korean biopharmaceutical company founded in 2000 that develops, manufactures, and globally distributes botulinum toxin products, hyaluronic acid dermal fillers, and dermacosmetics, selling exclusively to medical professionals across approximately 60 countries with ~40% domestic market share.

Ownership category

akta.pro rank

Product category

Medical Aesthetics / Biopharmaceutical Injectables

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Botulinum toxin products
• Hyaluronic acid fillers
• Medical aesthetic injectables
• Biopharmaceutical manufacturing
• Derma cosmetic products

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Botulinum Toxin Products: Revenue from botulinum toxin products including Neuronox/Neuronox, Innotox, Coretox, and NEWLUX sold to medical professionals globally. Products available in various dosages (25U, 50U, 100U, 150U, 200U)
2. Hyaluronic Acid Dermal Fillers: Revenue from filler products including Neuramis (Light Lidocaine, Lidocaine, Deep, Deep Lidocaine, Volume Lidocaine), Atiere (Classic, Intensive, Volume), and Potenfill sold to aesthetic clinics and medical professionals
3. Dermacosmetic Products: Revenue from Neuraderm brand including Clinic Derma and Basic Derma product lines (skin boosters, masks, moisturizers, cleansers)
4. Health Supplements: Revenue from Khan's Morning hangover cure and other health supplement products

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Medytox develops, manufactures, and sells botulinum toxin type A injectable products (Neuronox/Meditoxin, Innotox, Coretox, NEWLUX) and hyaluronic acid dermal fillers (Neuramis, Atiere, Potenfill) for medical aesthetic and therapeutic use. The company also markets derma cosmetic product lines under the Neuraderm brand (Clinic Derma, Basic Derma) and a hangover-relief health supplement (Khan's Morning). All medical products are sold exclusively to qualified healthcare professionals and exported to approximately 60 countries.

Product overview

Medytox is a global biopharmaceutical company and Korea's first botulinum toxin developer, offering a diversified portfolio of botulinum toxin type A products (Neuronox/Meditoxin, INNOTOX, Coretox, NEWLUX), hyaluronic acid dermal fillers (Neuramis, Atiere, Potenfill), dermacosmetics under the Neuraderm brand (Clinic Derma and Basic Derma lines), and health supplements (Khan's Morning). The company operates manufacturing facilities in South Korea (Gwanggyo R&D Center, Osong plants) and maintains global subsidiaries in Taiwan, Hong Kong, Thailand, Japan, and the USA, exporting to approximately 60 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Neuraderm: Derma cosmetic brand featuring neuroscience and dermatology research products including Clinic Derma and Basic Derma product lines
• Neuramis

Products and services

• Neuronox (Meditoxin) Botulinum toxin type A injectable for temporary improvement of moderate to severe glabellar wrinkles and therapeutic indications including benign essential eyelid spasms, pediatric cerebral palsy, and upper limb spasticity. Available in 50U, 100U, 150U, and 200U formulations. For medical professionals only.
• INNOTOX World's first non-animal derived liquid formulation botulinum toxin type A product. Available in 25U, 50U, and 100U formulations for temporary improvement of glabellar wrinkles. For medical professionals only.
• Coretox Botulinum toxin type A product for temporary improvement of moderate to severe glabellar wrinkles in adults aged 20 to 65. Available in 100U formulation. For medical professionals only.
• NEWLUX Botulinum toxin type A product (Clostridium botulinum toxin type A, Hall strain) for temporary improvement of moderate to severe glabellar wrinkles in adults aged 19 to 65. Available in 100U formulation. Sold via NUMECO (Neumeco) subsidiary. For medical professionals only.
• Neuramis Hyaluronic acid dermal filler product line including Light Lidocaine, Lidocaine, Deep, Deep Lidocaine, and Volume Lidocaine variants for temporary facial wrinkle improvement and mid-face volume enhancement. Carries CE marking for European market. For medical professionals only.
• Atiere Hyaluronic acid filler product line including Classic, Intensive, and Volume variants for tissue recovery and facial wrinkle improvement. Packaged as 2 x 1.0mL syringes. For medical professionals only.
• Potenfill Hyaluronic acid tissue recovery biomaterial as a single-use sterile medical device. 1.0mL packaging, stored at 2-25°C, 24-month shelf life. For medical professionals only.
• Neuraderm Clinic Derma Premium derma cosmetic product line including Core Time Ampoule, Age Defence Skin Booster, Repair Lifting Skin Booster, Hydro Brightening Skin Booster, Deep Calming Skin Booster, Age Defence Bio Mask, and Cream MD for anti-aging and skin care treatments. Consumer-facing product line under the Neuraderm brand.
• Neuraderm Basic Derma Entry-level derma cosmetic product line including Neuro Lacto Toner, Neuro Lacto Serum, Neuro Lacto Moisturizer, Calming Foam Cleanser, Calming Mist, Protective Facial Balm, and Intensive Sun Cream SPF 50+ PA++++. Consumer-facing product line under the Neuraderm brand.
• Khan's Morning Hangover cure health supplement containing lactic acid bacteria for hangover relief. Consumer product.
• NUVIJU (MT921) World's first cholic acid-based injection lipolysis product for submental fat reduction. Approved by the Korean Ministry of Food and Drug Safety. For medical professionals only.

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• AMG (Greek Medical Device and Cosmetics Distributor)coreChannel Partner/ Reseller/ Distributor · 8 June 2026Medytox's derma cosmetic brand 'Neuraderm' signed an exclusive supply contract with AMG, a Greek medical device and cosmetics distributor. The partnership enables simultaneous entry into seven European countries including Greece, Italy, Spain, and France. Medytox plans to leverage AMG's local distribution network to expand into online and offline sales channels while strengthening consumer touchpoints across the region. The goal is to grow Neuraderm into a representative K-derma cosmetics brand based on Medytox's over 20 years of neuroscience and dermatology research.
• Medytox Taiwan (Joint Venture)coreStrategic or Co-development PartnerTaiwan joint venture established as part of Medytox's global expansion strategy. Part of network that includes Taiwan, Hong Kong, Thailand joint ventures and Japan, Thailand, USA subsidiaries.
• Medytox Hong Kong (Joint Venture)coreStrategic or Co-development PartnerHong Kong joint venture established as part of Medytox's global expansion strategy for the greater China region.
• MedyCeles (Thailand Joint Venture)coreStrategic or Co-development PartnerThailand joint venture established as part of Medytox's global expansion strategy for the Southeast Asian market.
• MDT International Inc. (Japan Subsidiary)coreStrategic or Co-development Partner100% owned Japanese subsidiary managing sales and distribution in Japan, one of the key export markets for Medytox.
• Luvantas (USA Subsidiary)coreStrategic or Co-development Partner100% owned US subsidiary based in Irvine, California. Part of strategy to expand into the US market.
• NUMECO (Newmeco) - Domestic SubsidiarycoreStrategic or Co-development PartnerNUMECO (formerly Medytox Korea, renamed to Neumeco) is the domestic corporation business unit. Received domestic product approval from Ministry of Food and Drug Safety for 'Newlux injection 200 units' (Clostridium botulinum toxin type A) on June 19, 2026. The subsidiary commercializes next-generation toxin products including NEWLUX and METATOX.
• ICLAS (International Confederation for Laser Aesthetic Surgery)minorStrategic or Co-development PartnerMedytox participated in ICLAS 2026 industrial session, featuring speakers discussing Medytox's product portfolio including CORETOX and next-generation toxins from subsidiary NUMECO.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• AbbVie (Allergan Aesthetics): Global owner of Botox, the category-leading botulinum toxin, plus the CoolSculpting and facial aesthetics portfolio. AbbVie defines the standard Medytox must displace in the medical aesthetics channel and is the principal incumbent competitor worldwide.
• Galderma: Global dermatology and aesthetics company owning Dysport (botulinum toxin) and the Restylane HA filler line. Galderma overlaps directly with Medytox across both toxin and filler categories and competes in the same medical professional channel.
• Ipsen: Owner of Dysport (abobotulinumtoxinA) and an established aesthetics/neurology franchise. Ipsen is a direct botulinum toxin competitor to Medytox in Europe, Asia, and emerging markets.

Direct peers

• Evolus, Inc. US aesthetics company commercializing Jeuveau (prabotulinumtoxinA), a botulinum toxin positioned against Botox. Evolus targets the same medical professional channel as Medytox and represents a comparable go-to-market archetype for a newer-toxin entrant.
• Hugel, Inc. Korean botulinum toxin and dermal filler maker (Botulax/Letybo, TheChae). Hugel is Medytox's closest domestic rival, competing head-to-head across the same Korean and Asian aesthetics channels with a similar product portfolio and KOSDAQ listing.
• Daewoong Pharmaceutical: Korean pharmaceutical company behind Nabota, a botulinum toxin type A. Daewoong competes directly with Medytox's Neuronox and Innotox in Korea and across Asian export markets, leveraging comparable regulatory approvals and clinical claims.

Regional players

• Sinclair Pharma: Aesthetics company (now part of Huadong Medicine) with HA fillers (MaiLi) and collagen-stimulator products sold in Europe and Asia. Sinclair is a comparable premium aesthetic medical device peer operating in the same channels as Medytox's filler business.
• Croma-Pharma: Austria-based aesthetics company focused on HA fillers (Princess line), platelet-rich plasma, and botulinum toxin distribution across Europe. Croma competes most directly with Medytox in European markets Medytox is entering via AMG.

Emerging players

• Revance Therapeutics: Innovator of Daxxify, a longer-duration botulinum toxin, plus the RHA Collection of fillers. Revance competes with Medytox across toxins and fillers and illustrates the next-generation differentiation Medytox must match.
• BioPlus Co., Ltd. Korean botulinum toxin developer (Botulax competitor lineup) and emerging aesthetics player. BioPlus is a smaller Korean challenger that overlaps with Medytox in domestic toxin positioning and expanding Asian exports.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@medytox2699
• Facebookblog.naver.com/medytox_official

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries8 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medytox